IL107292D0 - Substituted benzylaminoquinuclidines - Google Patents
Substituted benzylaminoquinuclidinesInfo
- Publication number
- IL107292D0 IL107292D0 IL107292A IL10729293A IL107292D0 IL 107292 D0 IL107292 D0 IL 107292D0 IL 107292 A IL107292 A IL 107292A IL 10729293 A IL10729293 A IL 10729293A IL 107292 D0 IL107292 D0 IL 107292D0
- Authority
- IL
- Israel
- Prior art keywords
- benzylaminoquinuclidines
- substituted
- Prior art date
Links
- DTJXCCUWIKIZEX-UHFFFAOYSA-N N-benzyl-1-azabicyclo[2.2.2]octan-2-amine Chemical class data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300' height='300' x='0' y='0'> </rect>
<path class='bond-0' d='M 67.3258,187.82 L 26.5237,179.144' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 67.3258,187.82 L 95.2405,156.823' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 26.5237,179.144 L 61.3117,169.306' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 26.5237,179.144 L 13.6364,139.471' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 61.3117,169.306 L 76.1996,152.774' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 76.1996,152.774 L 78.3156,140.523' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 78.3156,140.523 L 80.4317,128.273' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 13.6364,139.471 L 41.5511,108.473' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 41.5511,108.473 L 56.8535,111.727' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 56.8535,111.727 L 72.1558,114.981' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 85.9666,128.273 L 90.6036,142.548' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 90.6036,142.548 L 95.2405,156.823' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 95.2405,156.823 L 110.543,160.077' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 110.543,160.077 L 125.845,163.33' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 146.06,154.375 L 155.009,144.438' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 155.009,144.438 L 163.957,134.501' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 163.957,134.501 L 204.759,143.177' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 204.759,143.177 L 217.647,182.851' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 214.627,146.551 L 223.648,174.322' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 204.759,143.177 L 232.674,112.18' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 217.647,182.851 L 258.449,191.527' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 258.449,191.527 L 286.364,160.529' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 256.437,181.294 L 275.977,159.596' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 286.364,160.529 L 273.476,120.856' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 273.476,120.856 L 232.674,112.18' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 265.621,127.715 L 237.059,121.642' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="start" x='77.7177' y='119.235' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='136.043' y='167.585' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='131.407' y='181.489' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>H</tspan></text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85' height='85' x='0' y='0'> </rect>
<path class='bond-0' d='M 18.5756,52.7158 L 7.01505,50.2575' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 18.5756,52.7158 L 26.4848,43.9331' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 7.01505,50.2575 L 16.8716,47.47' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 7.01505,50.2575 L 3.36364,39.0167' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 16.8716,47.47 L 21.0899,42.7859' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 21.0899,42.7859 L 21.7915,38.724' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 21.7915,38.724 L 22.4931,34.6621' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 3.36364,39.0167 L 11.2728,30.234' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 11.2728,30.234 L 16.1994,31.2816' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 16.1994,31.2816 L 21.1261,32.3292' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 23.4733,34.6621 L 24.979,39.2976' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 24.979,39.2976 L 26.4848,43.9331' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 26.4848,43.9331 L 31.4114,44.9807' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 31.4114,44.9807 L 36.3381,46.0283' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 39.7528,44.4954 L 42.8537,41.052' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 42.8537,41.052 L 45.9546,37.6087' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 45.9546,37.6087 L 57.5152,40.0669' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 57.5152,40.0669 L 61.1666,51.3078' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 60.3111,41.0227 L 62.8671,48.8914' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 57.5152,40.0669 L 65.4244,31.2842' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 61.1666,51.3078 L 72.7272,53.766' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 72.7272,53.766 L 80.6364,44.9833' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 72.157,50.8668 L 77.6935,44.7189' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 80.6364,44.9833 L 76.985,33.7425' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 76.985,33.7425 L 65.4244,31.2842' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 74.7592,35.6859 L 66.6668,33.9651' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="start" x='21.52' y='33.2832' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='38.0454' y='46.9823' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="start" x='36.732' y='50.922' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>H</tspan></text>
</svg>
 C1C(CC2)CCN2C1NCC1=CC=CC=C1 DTJXCCUWIKIZEX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4283135A JP2656699B2 (en) | 1992-10-21 | 1992-10-21 | Substituted benzylaminoquinuclidine |
Publications (1)
Publication Number | Publication Date |
---|---|
IL107292D0 true IL107292D0 (en) | 1994-01-25 |
Family
ID=17661684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL107292A IL107292D0 (en) | 1992-10-21 | 1993-10-14 | Substituted benzylaminoquinuclidines |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0665844B1 (en) |
JP (1) | JP2656699B2 (en) |
AT (1) | AT196140T (en) |
AU (1) | AU5165393A (en) |
CA (1) | CA2146259C (en) |
DE (1) | DE69329386T2 (en) |
DK (1) | DK0665844T3 (en) |
ES (1) | ES2149215T3 (en) |
FI (1) | FI114636B (en) |
GR (1) | GR3034498T3 (en) |
HU (1) | HUT65133A (en) |
IL (1) | IL107292D0 (en) |
MX (1) | MX9306527A (en) |
PT (1) | PT665844E (en) |
WO (1) | WO1994008997A1 (en) |
ZA (1) | ZA9307780B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2205016A1 (en) * | 1994-11-10 | 1996-05-23 | Hans-Jurgen Ernst Hess | Nk-1 receptor antagonists for the treatment of eye disorders |
FR2728166B1 (en) | 1994-12-19 | 1997-02-07 | ||
TW458774B (en) | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
FR2741262B1 (en) | 1995-11-20 | 1999-03-05 | Oreal | Use of a tnf-alpha antagonist for the treatment of cutaneous redness of neurogenic origin |
US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
US20060063766A1 (en) | 2004-07-15 | 2006-03-23 | Molino Bruce F | Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin |
ES2382814T3 (en) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment |
US7956050B2 (en) | 2005-07-15 | 2011-06-07 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
BRPI0913915A2 (en) | 2008-07-03 | 2015-10-13 | Neuraxon Inc | benzoxazine, benzothiazine, and related compounds having inhibitory activity of nos |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Inhibitors of akt activity |
KR20120034644A (en) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
EP2429296B1 (en) | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
EA023838B1 (en) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
JP6043285B2 (en) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
AU2012245455A1 (en) | 2011-04-21 | 2013-10-31 | Merck Sharp & Dohme Corp. | Insulin-Like Growth Factor-1 Receptor inhibitors |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
CA2892361A1 (en) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels |
EP2935263B1 (en) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
PL170513B1 (en) * | 1991-05-22 | 1996-12-31 | Pfizer | Method of obtaining novel derivatives of 3-amino quinuclidine |
-
1992
- 1992-10-21 JP JP4283135A patent/JP2656699B2/en not_active Expired - Fee Related
-
1993
- 1993-09-30 DK DK93922754T patent/DK0665844T3/en active
- 1993-09-30 AT AT93922754T patent/AT196140T/en not_active IP Right Cessation
- 1993-09-30 EP EP93922754A patent/EP0665844B1/en not_active Expired - Lifetime
- 1993-09-30 PT PT93922754T patent/PT665844E/en unknown
- 1993-09-30 WO PCT/US1993/009168 patent/WO1994008997A1/en active IP Right Grant
- 1993-09-30 AU AU51653/93A patent/AU5165393A/en not_active Abandoned
- 1993-09-30 CA CA002146259A patent/CA2146259C/en not_active Expired - Fee Related
- 1993-09-30 ES ES93922754T patent/ES2149215T3/en not_active Expired - Lifetime
- 1993-09-30 DE DE69329386T patent/DE69329386T2/en not_active Expired - Fee Related
- 1993-10-14 IL IL107292A patent/IL107292D0/en not_active IP Right Cessation
- 1993-10-20 HU HU9302965A patent/HUT65133A/en unknown
- 1993-10-20 MX MX9306527A patent/MX9306527A/en unknown
- 1993-10-20 ZA ZA9307780A patent/ZA9307780B/en unknown
- 1993-10-20 FI FI934626A patent/FI114636B/en active IP Right Grant
-
2000
- 2000-09-28 GR GR20000402187T patent/GR3034498T3/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FI934626A0 (en) | 1993-10-20 |
FI934626D0 (en) | |
HU9302965D0 (en) | 1993-12-28 |
DE69329386T2 (en) | 2001-01-04 |
JPH06135963A (en) | 1994-05-17 |
HUT65133A (en) | 1994-04-28 |
CA2146259C (en) | 1998-04-07 |
FI114636B1 (en) | |
WO1994008997A1 (en) | 1994-04-28 |
DK665844T3 (en) | |
FI114636B (en) | 2004-11-30 |
EP0665844B1 (en) | 2000-09-06 |
MX9306527A (en) | 1994-07-29 |
EP0665844A1 (en) | 1995-08-09 |
ZA9307780B (en) | 1995-04-20 |
DE69329386D1 (en) | 2000-10-12 |
CA2146259A1 (en) | 1994-04-28 |
PT665844E (en) | 2001-01-31 |
AU5165393A (en) | 1994-05-09 |
GR3034498T3 (en) | 2000-12-29 |
ES2149215T3 (en) | 2000-11-01 |
JP2656699B2 (en) | 1997-09-24 |
DK0665844T3 (en) | 2000-10-16 |
AT196140T (en) | 2000-09-15 |
FI934626A (en) | 1994-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP9300508A0 (en) | Compounds | |
GB9202238D0 (en) | Compounds | |
GB9215665D0 (en) | Compounds | |
GB9209628D0 (en) | Compounds | |
DE69332083D1 (en) | Polyolefinfasern | |
DE69316369D1 (en) | Oligonukleotid alkylphosphonothiate | |
DE69307495D1 (en) | Oligothionukleotide | |
DE69307690D1 (en) | Implantierbare penis-prothese | |
DE69325018D1 (en) | Pyrazolderivate | |
DE69310146D1 (en) | Riemenspannvorreichtung | |
DE69319731D1 (en) | Wässrige polyurethan-dispersionen | |
HU9303423D0 (en) | Catechin-diether-type pdeiv-inhibitors | |
IL119462A (en) | 1-trimethylphenyl-3-substituted 1H-pyrrol-2-amines | |
HUT67279A (en) | Powder-inhaler | |
HU9303579D0 (en) | Resin-free-succinimides | |
GB2269063B (en) | Auto-reclosers | |
HU9300184D0 (en) | Amin-oxides | |
LU90898I2 (en) | Levocetirizine-dihydrochloride | |
AU115931S (en) | Cuff-link | |
TW272940B (en) | / | |
DE69320476D1 (en) | Erythromycinderivate | |
HUT68483A (en) | Vintilated filtercigarette | |
IL119715D0 (en) | 5- hydroxy -3- phenyl - thiazolidin -4- ones | |
GB2267325B (en) | Autotensioner | |
GB9202791D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RH1 | Patent not in force |